Aristotle Capital Boston’s Supernus Pharmaceuticals SUPN Stock Holding History

Aristotle Capital Boston’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.5M	Sell	203,094 -31,409	-13%	-$1.6M	0.65%	70
2025 Q4	$11.7M	Sell	234,503 -70,770	-23%	-$3.44M	0.64%	70
2025 Q3	$14.6M	Sell	305,273 -503,122	-62%	-$20.3M	0.75%	60
2025 Q2	$25.5M	Sell	808,395 -64,293	-7%	-$2.06M	1.3%	25
2025 Q1	$28.6M	Sell	872,688 -203,180	-19%	-$7.2M	1.43%	21
2024 Q4	$38.9M	Sell	1,075,868 -118,358	-10%	-$4.17M	1.44%	20
2024 Q3	$37.2M	Sell	1,194,226 -8,940	-0.7%	-$279K	1.23%	28
2024 Q2	$32.2M	Buy	1,203,166 +63,320	+6%	+$1.84M	1.08%	35
2024 Q1	$38.9M	Sell	1,139,846 -19,982	-2%	-$595K	1.18%	29
2023 Q4	$33.6M	Sell	1,159,828 -28,153	-2%	-$746K	1.03%	38
2023 Q3	$32.8M	Buy	1,187,981 +26,034	+2%	+$792K	1.06%	35
2023 Q2	$34.9M	Buy	1,161,947 +6,798	+0.6%	+$238K	1.05%	34
2023 Q1	$41.9M	Buy	1,155,149 +28,268	+3%	+$1.09M	1.29%	20
2022 Q4	$40.2M	Sell	1,126,881 -30,672	-3%	-$1.07M	1.27%	22
2022 Q3	$39.2M	Sell	1,157,553 -110,187	-9%	-$3.59M	1.32%	15
2022 Q2	$36.7M	Buy	1,267,740 +9,673	+0.8%	+$277K	1.09%	26
2022 Q1	$40.7M	Sell	1,258,067 -27,805	-2%	-$852K	1.03%	30
2021 Q4	$37.5M	Sell	1,285,872 -32,237	-2%	-$978K	0.88%	43
2021 Q3	$35.2M	Buy	1,318,109 +256,456	+24%	+$6.88M	0.82%	48
2021 Q2	$32.7M	Buy	1,061,653 +88,360	+9%	+$2.71M	0.75%	54
2021 Q1	$25.5M	Sell	973,293 -48,333	-5%	-$1.35M	0.57%	82
2020 Q4	$25.7M	Sell	1,021,626 -50,826	-5%	-$1.09M	0.61%	74
2020 Q3	$22.4M	Buy	1,072,452 +44,614	+4%	+$1.01M	0.65%	63
2020 Q2	$24.4M	Buy	1,027,838 +287,199	+39%	+$6.35M	0.74%	50
2020 Q1	$13.3M	Sell	740,639 -16,864	-2%	-$354K	0.57%	72
2019 Q4	$18M	Buy	757,503 +13,511	+2%	+$328K	0.5%	88
2019 Q3	$20.4M	Buy	743,992 +639,961	+615%	+$19M	0.6%	72
2019 Q2	$3.44M	Buy	+104,031	New	+$3.56M	0.11%	123